Valuation: Insulet Corporation

Market Cap 10.16B 8.8B 8.25B 7.52B 14.16B 969B 14.39B 97.17B 37.94B 485B 38.13B 37.3B 1,619B P/E 2026 *
23.9x
P/E 2027 * 19.2x
Enterprise Value 10.21B 8.85B 8.29B 7.56B 14.23B 974B 14.46B 97.65B 38.12B 488B 38.32B 37.49B 1,627B EV / Sales 2026 *
3.1x
EV / Sales 2027 * 2.63x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -
1 day+0.95%
1 week+5.13%
Current month-11.44%
1 month-9.64%
3 months-1.61%
6 months-39.67%
Current year-48.48%
1 week 138.7
Extreme 138.7
146.82
1 month 126.4
Extreme 126.4
172.92
Current year 126.4
Extreme 126.4
299.8
1 year 126.4
Extreme 126.4
354.88
3 years 125.82
Extreme 125.82
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 30.69
Extreme 30.69
354.88
Manager TitleAgeSince
Chief Executive Officer 55 27/04/2025
Director of Finance/CFO 53 29/09/2025
Compliance Officer 50 30/11/2022
Director TitleAgeSince
Chairman 61 31/12/2018
Director/Board Member 61 26/07/2015
Director/Board Member 59 09/08/2017
Date Insider Type Main position Quantity % Market Cap.
01/08/26 Tax

Head of Human Resources

-244 0.0003%
01/07/26 Free

Director

1,355 0.0019%
01/07/26 Other

Director

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
+0.95%+5.13%-52.56%-35.00% 10.16B
+0.32%+3.07%-14.01%+5.66% 193B
-0.20%+5.42%-2.51%+8.54% 116B
-1.32%-4.62%+6.52%+65.45% 59.16B
+0.32%+3.92%+38.42%+65.14% 55.75B
-0.88%+2.77%-7.14%-35.54% 49.57B
+0.75%+10.19%+14.41%-18.09% 34.52B
+0.23%+3.10% - - 31.22B
-1.74%-0.70%+40.59%-12.31% 24.36B
+1.98%+12.62%-2.80%+25.91% 24.25B
Average +0.04%+4.20%+2.32%+7.75% 59.75B
Weighted average by Cap. -0.03%+3.56%+0.12%+12.66%

Financials

2026 *2027 *
Net sales 3.29B 2.85B 2.67B 2.44B 4.58B 314B 4.66B 31.45B 12.28B 157B 12.34B 12.08B 524B 3.74B 3.25B 3.04B 2.77B 5.22B 357B 5.3B 35.82B 13.99B 179B 14.06B 13.75B 597B
Net income 427M 370M 347M 316M 595M 40.72B 604M 4.08B 1.59B 20.38B 1.6B 1.57B 67.99B 535M 464M 435M 397M 746M 51.09B 758M 5.12B 2B 25.57B 2.01B 1.97B 85.31B
Net Debt 49.62M 43.01M 40.32M 36.77M 69.18M 4.74B 70.29M 475M 185M 2.37B 186M 182M 7.91B -322M -279M -262M -239M -449M -30.77B -457M -3.08B -1.2B -15.4B -1.21B -1.18B -51.38B
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
13/08/26 US$146.44 +0.95% 1,368,507
12/08/26 US$145.06 +0.25% 1,570,825
11/08/26 US$144.70 +1.30% 1,249,815
10/08/26 US$142.85 +1.19% 1,505,082
07/08/26 US$141.17 +1.34% 1,591,344
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
146.44USD
Average target price
171.91USD
Spread / Average Target
+17.39%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PODD Stock